NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein

Neoplasma

Volumn 55, Issue 3, 2008, Pages 200-204

  Chen, X J ^a   Xiao, W ^a   Qu, X ^a   Zhou, S Y ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Non small cell lung carcinoma; NS 398

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GEMCITABINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2 INHIBITOR; DEOXYCYTIDINE; DRUG DERIVATIVE; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; NITROBLUE TETRAZOLIUM TEST; PROTEIN DETERMINATION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2 INHIBITORS; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; NITROBENZENES; SULFONAMIDES; UP-REGULATION;

EID: 49049094938     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. CROFFORD LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997; 49: 15-19. (Pubitemid 27314722)
2. DUBOIS RN, ABRAMSON SB, CROFFORD L, et al. Cyclooxygenase in biology and disease. Faseb J 1998; 12: 1063-1073.
3. HIDA T, YATABE Y, ACHIWA H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
4. SAWAOKA H, KAWANO S, TSUJI S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998; 274: G1061-G1067. (Pubitemid 28304229)
5. LIU XH, YAO S. KIRSCHENBAUM A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245-4249.
6. ERICKSON BA, LONGO WE, PANESAR N, et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999; 81: 101-107. (Pubitemid 29393786)
7. TUCKER ON, DANNENBERG AJ, YANG EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-990. (Pubitemid 29135954)
8. TSUJII M, KAWANO S, TSUJII S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
9. HUANG M, STOLINA M, SHARMA S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and downregulation of interleukin 12 production. Cancer Res 1998; 58: 208-1216.
10. TSUJII M, KUWANO S, DUBOIS RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340. (Pubitemid 27157312)
11. MARGARITA SB, ABEL SA, MIGUEL AP. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101: 1220-1235.
12. MASSAQUE J, POLYAK K. Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 1995; 5: 91-96.
13. SHERR CJ, ROBERTS JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
14. SCHORGE JO, LEA JS, ELIAS KJ, et al. p16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 2004; 190: 668-673.
15. GOTTLIEB TM, OREN M. p53 in growth control and neoplasia, Biochim Biophys Acta 1996; 1287: 77-102.
16. HELIN K, LEES JA, VIDAL M, et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992; 70: 337-350.
17. MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEVA I, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (Lond) 1998; 391: 601-605. (Pubitemid 28157604)
18. ISHII T, FUJISHIRO M, MASUDA M, et al. Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells. Eur Respir J 2004; 23: 665-670. (Pubitemid 38618133)
19. LINCET H, POULAIN L, REMY JS, et al. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000; 161: 17-26.
20. SHIBATA MA, YOSHIDOME K, SHIBATA E, et al. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.Cancer Gene Ther 2001; 8: 23-35.
21. ANDREI LG, ANGELA L, TYNER. The role of the Cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics 2002; 1: 639-649.
22. BISSONNETTE N, HUNTING DJ. p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 1998; 16: 3461-3469.
23. BUNZ F, HWANG PM, TORRANCE C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Investig 1999; 104: 263-269.
24. SUPRIATNO HK, HOQUE MO. Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 2002; 38: 730-736. (Pubitemid 34880113)
25. KATAYOSE Y, KIM M, RAKKAR AN, Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57: 5441-5445.
26. GARTEL AL, TYNER AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999; 246: 280-289.
27. EL-DEIRY WS, TOKINO T, WALDMAN T, et al. Topological control of p21 (WAF1/CIP1) expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
28. SHEAFF RJ, SINGER JD, SWANGER J, et al. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000; 5: 403-410.
29. TOUITOU R, RICHARDSON J, BOSE S, et al. A degradation signal located in the C-terminus of 21WAF1/ CIP1 is a binding site for the C8- subunit of the 20S proteasome. Embo J 2001; 20: 2367-2375.
30. HUANG YC, CHUANG LY, HUNG WC. Mechanisms underlying nonsteroidal anti-Inflammatory drug-induced p27Kip1 expression. Mol Pharmacol 2002; 62: 1515-1521.